Background-Dalcetrapib did not improve clinical outcomes, despite increasing high-density lipoprotein cholesterol by 30%. These results differ from other evidence supporting high-density lipoprotein as a therapeutic target. Responses to dalcetrapib may vary according to patients' genetic profile. Methods and Results-We conducted a pharmacogenomic evaluation using a genome-wide approach in the dal-OUTCOMES study (discovery cohort, n=5749) and a targeted genotyping panel in the dal-PLAQUE-2 imaging trial (support cohort, n=386). The primary endpoint for the discovery cohort was a composite of cardiovascular events. The change from baseline in carotid intima-media thickness on ultrasonography at 6 and 12 months was evaluated as supporting evidence. A single-nucleotide polymorphism was found to be associated with cardiovascular events in the dalcetrapib arm, identifying the ADCY9 gene on chromosome 16 (rs1967309; P=2.41×10 -8 ), with 8 polymorphisms providing P<10 -6 in this gene.
H igh-density lipoprotein (HDL)-based therapies have yielded disappointing results, [1] [2] [3] [4] which have led to questioning of the HDL hypothesis. Cholesteryl ester transfer protein mediates the transfer of cholesteryl esters from HDL to apolipoprotein B-containing particles, such as low-density lipoproteins (LDLs). 5 Torcetrapib, the first cholesteryl ester transfer protein inhibitor to be evaluated in a large clinical trial, caused excess morbidity and mortality despite increasing HDL-cholesterol levels by ≈70% although elevations of aldosterone levels and blood pressure observed in some patients may have contributed to the negative findings. 3 Dalcetrapib is another cholesteryl ester transfer protein inhibitor that raises HDL-cholesterol levels by ≈30%, without effects on circulating neurohormones. 6 The dal-OUTCOMES trial was designed to test whether dalcetrapib could modify cardiovascular risk in patients with a recent acute coronary syndrome. 4 Dalcetrapib failed to improve clinical outcomes among the 15 871 patients of the dal-OUTCOMES study, with no subgroups defined by baseline clinical or biochemical characteristics appearing to benefit from therapy. 4 These results are at odds with those from epidemiological, clinical, rare family genetic, animal model, cellular, and molecular studies that support HDL as a therapeutic target. In contrast, HDL has been shown to lose some of its beneficial properties to varying degrees in patients with coronary artery disease. 7 We hypothesized that responses to dalcetrapib vary among patients, based on their genetic profile. Accordingly, we conducted a pharmacogenomic evaluation using a genome-wide approach in the dal-OUTCOMES study and then in the dal-PLAQUE-2 imaging trial 8 to test for the association of genetic factors with both cardiovascular events and vascular disease changes when treated with dalcetrapib.
Methods

The dal-OUTCOMES Trial
The dal-OUTCOMES study was a phase 3 clinical trial testing the efficacy of the investigational cholesteryl ester transfer protein inhibitor dalcetrapib (F. Hoffmann-La Roche), as previously described. 4 Patients who were clinically stable 4 to 12 weeks after a recent acute coronary syndrome were randomized in a 1:1 ratio to dalcetrapib 600 mg daily or placebo on top of evidence-based medical care. Cardiovascular events were adjudicated by an independent clinical endpoint committee. For the pharmacogenomics study, 6338 patients were recruited from April 2008 to July 2010 at 461 sites in 14 countries and provided written informed consent to participate in the genetic study of the dal-OUTCOMES trial. DNA was extracted from whole blood. After genomic data cleanup, samples from 5749 white patients were used for the discovery genome-wide association study (GWAS).
The dal-PLAQUE-2 Trial
The dal-PLAQUE-2 study 8 was a phase 3b multicenter, doubleblind, randomized, placebo-controlled, parallel group trial designed to evaluate the effect of dalcetrapib on atherosclerotic disease progression in patients with evidence of coronary artery disease and carotid intima-media thickness (IMT) of ≥0.65 mm in the far wall of the common carotid arteries, as assessed by B-mode ultrasonography. A total of 931 patients was randomized to receive dalcetrapib 600 mg daily or matching placebo with intended treatment duration of 24 months. However, the trial was terminated prematurely concurrent with the termination of dal-OUTCOMES (the latter because of futility). Patients continued study medication until they returned for follow-up carotid imaging at 12 months. Carotid B-mode ultrasound recordings at baseline, month 6, and month 12 were analyzed centrally at the core laboratory of the Montreal Heart Institute (Methods in the Data Supplement). IMT was analyzed on the far wall of the common carotid arteries. 9 A segment of 10 mm in length of the common carotid artery was analyzed on serial examinations using an automated edge detection software (Carotid Analyzer; Medical Imaging Applications, Coralville, IA). Among the 411 participants in the dal-PLAQUE-2 trial who consented to the genetic study, 386 had imaging measures at baseline, 6 months, and 12 months (194 and 192 in the dalcetrapib and placebo arms, respectively). DNA was extracted from whole blood. The research protocols were approved by the relevant institutional review boards or ethics committees, and all human participants gave written informed consent.
Genotyping and Imputation
The Illumina Infinium HumanOmni2.5Exome-8v1_A BeadChip, including 2 567 845 genetic variants (Illumina, San Diego, CA) was used for the discovery GWAS of 5749 white participants to the dal-OUTCOMES study. Genome-wide imputation was performed using IMPUTE2 (version 2.3.1). 10 Phasing was performed using the shapeit2 algorithm (version 2r790). 11 A total of 28 846 501 genetic variants with imputation probability of ≥0.90 and completion rate of ≥98% were obtained. For the genome-wide analysis, 5 543 264 imputed genetic variants (5 162 068 single-nucleotide polymorphism [SNP] and 381 196 indels) with minor allele frequency >5% were used, including 1 223 798 which were genotyped on the HumanOmni2.5Exome-8v1_A chip. A Sequenom panel was used to genotype, in the ADCY9 gene, 5 imputed SNPs with P<10 -6 and 15 genotyped SNPs with P<0.05 identified in the discovery GWAS, along with 7-SNPs selected based on literature and functional prediction. The panel was used to genotype both the dal-OUTCOMES and the dal-PLAQUE-2 samples. Additional Methods are available in the Data Supplement.
Statistical Analysis
Statistical tests performed on genetic data were 2 sided. The genomewide significance threshold P<5×10 -8 was used for the discovery GWAS to adjust for the multiple testing of genetic variants. The dalcetrapib treatment arm was used for the discovery GWAS and significant genetic variants were next tested to confirm absence of association in the placebo arm and to test for gene-by-treatment interaction with both arms. The discovery GWAS was conducted using a Cox proportional hazards model for time to occurrence of events with 5 543 264 genetic variants of minor allele frequency ≥0.05. Analyses were performed using JMP Genomics software version 6.1 for genotyped data and using Lifelines (version 0.4.2) to compute Cox proportional hazards analysis of dosage data from imputation. All results with P<10 -6 have been validated in SAS software (version 9.3; SAS Institute Inc, Cary, NC) with and without the imputed genotypes and the assumption of proportional hazards has been verified. Cardiovascular events were prespecified as occurrence of the dal-OUTCOMES study primary outcome (coronary heart disease death, resuscitated cardiac arrest, nonfatal myocardial infarction, unstable angina with objective evidence of ischemia, and atherothrombotic stroke) with the addition of unanticipated coronary revascularization (an adjudicated secondary endpoint in the parent trial). Unanticipated coronary revascularizations were included in the primary endpoint of the pharmacogenomic study to increase the number of relevant cardiovascular events because the pharmacogenomic analysis included a smaller group of patients than the parent trial. The 1-degree of freedom additive genetic test was used. The Cox proportional hazards model included sex as a covariate and the first 5 principal components of population structure. Rare variants from the genotyping chip (minor allele frequency <0.05) were analyzed using SKAT with the β-weighting function using a 1 =1 and a 2 =25. 12 For tests of absolute changes in lipids, the baseline value of the tested lipid was added as covariate. For the dal-PLAQUE-2 population, a mixed regression model for repeated measures analysis was performed with SAS software; the tested endpoint was the mean IMT of common carotid arteries at the 6-and 12-month visits, using the baseline measure as covariate. Adjustment of the significance threshold for multiple testing of the 27-SNPs genotyped on the Sequenom panel was not applied because of the highly correlated nature of the selected SNPs. As reference, the number of independent tests (M eff ) was estimated using the method of Gao et al 13 to M eff =8, using the dal-OUTCOMES population sample. Additional Analytic Methods are available in the Data Supplement.
Results
Characteristics of Study Populations
An overview of the characteristics of dal-OUTCOMES study participants is provided in Table 1 and in the Data Supplement. The proportion of participants randomly assigned to dalcetrapib in the pharmacogenomic substudy (49.52%) was comparable with that of the global dal-OUTCOMES trial 
Discovery GWAS in the dal-OUTCOMES Trial
Of 5 543 264 common genetic variants analyzed, a single region with genome-wide significance was found to be associated with cardiovascular events by Cox proportional hazards modeling in the dalcetrapib arm, identifying SNPs in the ADCY9 gene on chromosome 16 ( Figure 1 ). The region includes a single genotyped SNP (rs1967309), which passed the significance threshold (P=2.41×10 -8 ; Table 2 ), and 2 imputed SNPs (rs2531971 and rs12920508) which saw their P values increase above the threshold on follow-up genotyping (P=7.74×10 -8 , 3.18×10 -7 , respectively; Table 3 ). SNP rs1967309 has a minor allele frequency of 0.41, and the additive genetic effect of 1 allele A has a hazard ratio (HR)=0.65 (95% confidence interval [CI], 0.56-0.76) for cardiovascular events in the dalcetrapib arm ( Table 2 ). Neighboring SNPs in linkage disequilibrium with rs1967309 were located in a common recombination block ( Figure 2 ). Overall, the region identified 3 genotyped SNPs and 5 imputed SNPs in the ADCY9 gene with P<10 -6 . None of the 835 255 rare genetic variants analyzed in 36 268
SKAT gene sets passed the significance threshold. The joint analysis of the 59 variants in the ADCY9 gene by SKAT provided a P=0.989. The main association between rs1967309 and cardiovascular events (P=2.4×10 -8 ) was robust to further adjustment for baseline hypertension (P=3. Table 2B ). The gene-by-treatment arm interaction term was indicative of a statistical interaction (P=0.0014; β=−0.340). Stratification by genotypes in the dalcetrapib arm shows that homozygotes for the minor allele (AA) and heterozygotes (AG) at rs1967309 have, respectively, HR=0.40 (95% CI, 0.28-0.57) and HR=0.68 (95% CI, 0.55-0.84) for cardiovascular events when compared with reference GG homozygotes ( Figure 3 ). Considering only patients with the homozygous genotype AA at rs1967309 (n=961), there was a 39% reduction in the prespecified composite endpoint of coronary heart disease death, resuscitated cardiac arrest, nonfatal myocardial infarction, nonfatal ischemic stroke, unstable angina or unanticipated coronary revascularization with dalcetrapib compared with placebo (HR, 0.61; 95% CI, 0.41-0.92; Table II 
Supporting Evidence From the dal-PLAQUE-2 Trial
Of the 27-SNPs selected for genotyping by Sequenom, 20 SNPs in the ADCY9 gene had P<0.05 in the discovery cohort. We tested those SNPs in the dal-PLAQUE-2 trial to obtain supporting evidence from imaging data obtained after 6 and 12 months of treatment in the dalcetrapib arm (n=194). Ten of 20 SNPs provided association with IMT measures in dal-PLAQUE-2 (P<0.05, Table 3 ). Notably, marker rs2238448 (which was in linkage disequilibrium with rs1967309 [r 2 =0.80]) was associated with IMT in dal-plaque-2 (P=0.009) and with events Table 3 ). None of the genotyped SNPs showed association in the placebo arm (all P>0.05). Only the gene-by-treatment interaction term of rs2531967 reached significance (P=0.024) in dal-PLAQUE-2, probably because of the small sample size. SNP rs1967309 did not reach significance for association with change in IMT in dal-PLAQUE-2 (P=0.114), but the reduction in IMT was of similar magnitude to that with rs2238448 and consistent with the findings in dal-OUTCOMES. After 12 months of treatment with dalcetrapib, changes in IMT were -0.021±0.083 mm in AA homozygotes, -0.001±0.048 mm for heterozygotes, and +0.005±0.042 mm for GG homozygotes at rs1967309. When genotyped in the dal-OUTCOMES population, SNP rs2238448 was associated with cardiovascular events in the dalcetrapib treatment arm with borderline GWAS significance (P=8.88×10 -8 ; Table 3 ). When considering only patients homozygous for the minor allele at rs2238448 (n=1188), there was a 34% reduction in the prespecified Table V in the Data Supplement). Stratification for patients who were homozygous for the minor alleles of both rs1967309 and rs2238448 (n=951) provided a reduction of events with dalcetrapib compared with placebo of 39% (HR, 0.61; 95% CI, 0.400.92), and patients homozygous for the minor alleles at rs1967309 or rs2238448 (n=1192) had a reduction of events with dalcetrapib when compared with those with placebo of 33% (HR, 0.67; 95% CI, 0.47-0.95).
Plasma Lipids
Genotypes of the rs1967309 SNP were significantly associated with changes over time in lipids induced by dalcetrapib in dal-OUTCOMES. Using univariate statistics, genotypes were associated with change in total cholesterol at 1 month (P=0.0001; P=0.004 when controlling for sex and genetic 
Discussion
This pharmacogenomic study demonstrates that cardiovascular responses to dalcetrapib are determined by the genetic profile of patients with coronary artery disease. Indeed, several polymorphisms in the ADCY9 gene influenced the effects of dalcetrapib on cardiovascular clinical outcomes and changes over time in carotid atherosclerosis. Most of these polymorphisms are correlated (in linkage disequilibrium; Figure 2 ; Figure VII in the Data Supplement) in the same region of the gene. For the polymorphic nucleotide rs1967309, patients with the AA genotype (minor or less common, allele) benefited from a reduction in cardiovascular events of 39% when treated with dalcetrapib compared with placebo, whereas those with the GG genotype (major allele) were exposed to a 27% increase in risk. Heterozygous patients with the AG genotype had an intermediate response.
When turning to rs2238448, patients homozygous for the minor allele and receiving dalcetrapib experienced protection against cardiovascular outcomes (versus placebo) as well as regression of carotid IMT, although patients with 2 copies of the major allele had worse clinical outcomes and increased carotid thickening. All of the other polymorphisms in the ADCY9 gene displayed similar directional effects (eg, protection against cardiovascular events in dal-OUTCOMES and regression of atherosclerosis in dal-PLAQUE-2) on responses to dalcetrapib. A total of 8 polymorphisms was associated with P values <10 -6 in the pharmacogenomic study of the dal-OUT-COMES trial, with the prespecified primary composite endpoint of coronary heart disease death, resuscitated cardiac arrest, nonfatal myocardial infarction, nonfatal ischemic stroke, unstable angina with objective evidence of ischemia, or unanticipated coronary revascularization. Of these 8 SNPs in the ADCY9 gene, a single SNP was associated with a P value less than the established significance threshold of 5×10 -8 . These results were only observed with dalcetrapib, not in the placebo arm, and there were statistical interactions between the polymorphisms and the study arm (dalcetrapib versus placebo) in the association with clinical events thus strengthening the link with the ADCY9 gene. HRs were similar when coronary revascularizations were removed from the analysis, which provided a direct comparison with the primary composite endpoint of the parent dal-OUTCOMES trial (coronary heart disease death, resuscitated cardiac arrest, nonfatal myocardial infarction, nonfatal ischemic stroke, or unstable angina). All 8 polymorphisms were in strong linkage disequilibrium (r 2 >0.77), which reinforces the postulate that this region of the ADCY9 gene determines clinical responses to dalcetrapib.
We then evaluated these polymorphisms in the dal-PLAQUE-2 trial, 8 a clinical study which showed globally a neutral effect of dalcetrapib on carotid wall imaging (as was the case for cardiovascular events in dal-OUTCOMES). The objective of the pharmacogenomic analysis of this second study was to provide evidence in support of our observation of a reduction of cardiovascular events with dalcetrapib in the pharmacogenomic study of dal-OUTCOMES. Despite the smaller sample size of the dal-PLAQUE-2 trial, 10 SNPs were associated with dalcetrapib-induced changes over time in common carotid IMT with P values <0.05, and 3 of them had values <0.01. The relationship between genotypes and carotid imaging was linear in the dalcetrapib arm: patients with no protective allele experienced an increase in IMT, those with 1 allele had a neutral result, and the subset of patients with 2 protective alleles benefited from the regression of IMT. Interestingly, this benefit emerged at the first follow-up imaging examination performed after 6 months of therapy in the dal-PLAQUE-2 study, which is temporally concordant with the early separation of the curves of accumulating clinical events in the dal-OUTCOMES trial (Figure 3) .
ADCY9 is the ninth, least well characterized and widely distributed isoform of adenylate cyclase, the membranebound enzyme responsible for the formation of cAMP from ATP. 14 Adenylate cyclase transducts various extracellular stimuli into intracellular signaling and is regulated by different factors, including G-protein-coupled receptors. Although ADCY9 is known to be stimulated by β-adrenergic receptor activation, the underlying mechanism linking that gene with cardiovascular responses to dalcetrapib is not yet clear. Polymorphisms in the ADCY9 gene have been shown to affect individual response to inhaled therapy in patients with asthma. 15 Recently, another ADCY9 gene polymorphism was shown to be associated with bodymass index and clinical classes of obesity. 16 In our study, polymorphisms in the ADCY9 gene influenced responses to dalcetrapib in terms of body mass index, weight, plasma LDL-cholesterol, LDL/HDL cholesterol ratio, and triglycerides (Figures VI and VII in the Data Supplement). These dalcetrapib-associated changes were statistically significant albeit small and were in the direction opposite to that expected: patients with the homozygous genotype for the major allele (eg, GG homozygotes for rs1967309) and hence exposed to a higher risk of cardiovascular events and progression of carotid atherosclerosis had mild decreases in body-mass index, weight and those plasma lipid fractions. Whether this counterintuitive finding is related to altered β-adrenergic signaling 15 or to other factors will need further investigations to elucidate the reasons for the increased cardiovascular risk incurred by this subset of patients when treated with dalcetrapib.
Dalcetrapib has been shown to increase cellular cholesterol efflux in patients with coronary artery disease. 17 Changes in cholesterol content of cellular membranes have been shown to lead to redistribution of G proteins and adenylate cyclase, which alters the interactions between the adrenergic receptor and its signaling partners and production of cAMP. 18 Such changes in adrenergic signal transduction could potentially be affected by polymorphisms in the ADCY9 gene. Alternatively, another hypothesis for the interaction between ADCY9 polymorphisms and responses to dalcetrapib could be related to the effects of the signaling cascade triggered by ADCY9 activation on ATP-binding cassette A1-mediated cholesterol efflux via ADCY9-dependent cAMP production and protein kinase A activation. 19, 20 Other molecular mechanisms and pathways could also be at play to explain our results.
The population frequency of the protective alleles of the ADCY9 gene polymorphisms identified in the current study ranged from 41% to 46%, and patients homozygous for these alleles represented ≈20% of the trial population. The prevalence of these genotypes is comparable with those reported in reference populations, such as the 1000 Genomes. 21 The difference in overall mortality among the entire dal-OUT-COMES trial (2.95%) and the genotyped subgroup (2.32%) suggests that patients with a better outcome were more likely to consent to participate in the pharmacogenomic study. This bias, however, would actually be expected to decrease the ability to identify genetic factors associated with cardiovascular events, including cardiovascular death. Furthermore, as cardiovascular deaths represent a minor fraction of cardiovascular events in this study it is highly unlikely to have contributed to false-positive genetic associations.
The selection of the polymorphism to be used to guide therapy with dalcetrapib should be carefully considered. rs1967309 was the only genotyped polymorphism genomewide that was significantly (2.4×10 -8 ) associated with cardiovascular events in the dalcetrapib arm in dal-OUTCOMES, leading to a reduction of 39% in our primary composite endpoint (coronary heart disease death, resuscitated cardiac arrest, nonfatal myocardial infarction, nonfatal stroke, unstable angina, or unanticipated coronary revascularization) compared with placebo. In comparison, rs2238448 did not pass the statistical threshold for significance in dal-OUTCOMES (8.88×10 -8 ) and was associated with a smaller reduction in the primary composite endpoint (≈34%) compared with rs1967309. In the dal-PLAQUE-2 trial, the magnitude of the effect of dalcetrapib according to genotypes at rs1967309 was numerically similar to that for rs2238448 (albeit statistically significant for rs2238448 and trending for rs1967309). The values were −0.021 and −0.027 mm in homozygotes for the minor allele for rs1967309 and rs2238448, respectively, and +0.005 and +0.009 mm in homozygotes for the major allele. To determine which polymorphism(s) should be selected for the next trial focused on clinical outcomes and ultimately for clinical use, we think that more importance should be assigned to the effects on clinical outcomes observed in dal-OUTCOMES with 5749 patients than to those on imaging seen in dal-PLAQUE-2 with 386 patients. We have also considered the possibility of using a combination of rs1967309 and rs2238448 ( Table V in the Data  Supplement) . Patients who are homozygous for the minor allele for both rs1967309 and rs2238448 represent a similar percentage of the population and benefited from a similar reduction in our primary composite endpoint of cardiovascular events compared with patients homozygous for the minor allele of rs1967309. Although patients who are homozygous for the minor allele for rs1967309 or rs2238448 represent 21% of the population, their benefit seemed to be smaller (reduction in the primary composite endpoint of 33.1%) compared with patients homozygous for the minor allele of rs1967309 (reduction of 39%). In the next clinical trial to confirm our finding, the expected effect size in the genetic subset will have a large impact on the study size. Because of this, we think that rs1967309 should be used in the next clinical trial.
In conclusion, the effects of dalcetrapib on atherosclerotic outcomes are determined by polymorphisms in the ADCY9 gene, with ≈1 in 5 patients having the appropriate genetic profile and thus deriving substantial protection against cardiovascular events in our study. A prospective pharmacogenomics-guided clinical trial should be performed in these responsive patients to allow regulatory review of results and provide personalized cardiovascular therapy with dalcetrapib.
